EUVIMEDEUVIMED entdecken
Crossref

Extended Half‐Life Recombinant Factor VIII Conjugated With Modifying Substances Does Not Affect Fibrin Clot Formation or Stability in Haemophilia A Blood Samples

Naruto Shimonishi iD, Keiji Nogami

Haemophilia · 2026-11 · 32 (6) · 1522-1531

DOI: 10.1111/hae.70361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 24.07.2026. Verfasst von Naruto Shimonishi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Nara Medical University, Nara, Japan. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A, Fibrin, Blood Coagulation. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Bayer Special Project Awards.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Various extended half‐life recombinant factor VIII (EHL‐FVIII) products have been designed to improve the pharmacokinetic properties of FVIII, allowing prolonged haemostatic coverage and reducing the injection burden in people with haemophilia A. Nevertheless, the influence of direct molecular attachment on fibrin clot formation and stability remains to be investigated.

Aim

To investigate the stability and architecture of fibrin clots in the presence of various types of EHL‐FVIII.

Methods

Three EHL‐FVIII products with direct attachment modifications (damoctocog alfa pegol, efraloctocog alfa, and rurioctocog alfa pegol) and two standard FVIII (turoctocog alfa and rurioctocog alfa) were added to FVIII‐deficient whole blood and plasma at various concentrations for functional comparison. Under whole‐blood conditions, functional assays were performed using rotational thromboelastometry (ROTEM) and a microchip flow‐chamber system (T‐TAS). Under plasma‐based conditions, fibrin fibres were directly observed by electron microscopy and coagulation function was assessed using clot waveform analysis (CWA). Anticoagulant and fibrinolytic activities were evaluated by CWA with the addition of activated protein C and tissue plasminogen activator, respectively.

Results

At equivalent activity levels, none of the assays revealed significant differences among the three EHL products or the two standard products. All contributed comparably to fibrin clot formation and stability, as well as to anticoagulation and fibrinolysis functions.

Conclusion

Direct modification by PEGylation or IgG‐Fc fusion to impart EHL characteristics preserves the functional properties of native FVIII.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIHemophilia AFibrinBlood CoagulationHumansHalf-LifeRecombinant Proteins

Stichwörter der Autor:innen

PEGylationblood coagulationfactor VIIIfibrinhaemophilia Ascanning electron microscopy

Substanzen

Factor VIIIFibrinRecombinant Proteins

Autor:innen und Institutionen

  • Department of Pediatrics, Nara Medical University, Nara, Japan.
  • The Course of Thrombosis and Hemostasis Molecular Pathology, Nara Medical University, Nara, Japan.

ORCID-Profile: Naruto Shimonishi

Förderung

  • Bayer Special Project Awards

Zitieren

APA

Shimonishi, N., & Nogami, K. (2026). Extended Half‐Life Recombinant Factor VIII Conjugated With Modifying Substances Does Not Affect Fibrin Clot Formation or Stability in Haemophilia A Blood Samples. Haemophilia, 32(6), 1522-1531. https://doi.org/10.1111/hae.70361

Vancouver

Shimonishi N, Nogami K. Extended Half‐Life Recombinant Factor VIII Conjugated With Modifying Substances Does Not Affect Fibrin Clot Formation or Stability in Haemophilia A Blood Samples. Haemophilia. 2026;32(6):1522-1531. doi:10.1111/hae.70361

BibTeX
@article{Shimonishi2026,
  author = {Shimonishi, Naruto and Nogami, Keiji},
  title = {Extended Half‐Life Recombinant Factor VIII Conjugated With Modifying Substances Does Not Affect Fibrin Clot Formation or Stability in Haemophilia A Blood Samples},
  journal = {Haemophilia},
  year = {2026},
  volume = {32},
  number = {6},
  pages = {1522--1531},
  doi = {10.1111/hae.70361}
}
Kostenlos starten →